Weekly Brief / Issue 11

China Capital Markets Weekly: A Medical Approval Is Not Yet a Revenue Stream

Neuracle's brain-computer interface filing separates clinical progress from commercial revenue as semiconductor replies test the assumptions behind growth

11 min read

Graphite and colored-pencil illustration of a neurophysiology research laboratory with signal recording equipment and a rehabilitation glove
Neuracle 2025 revenueCNY108.5mUpdated prospectus, PDF pp.30–31
H1 2026 operating cash flow−CNY36.6mNeuracle; not a full-year comparison
Invasive BCI product revenueNone yetDuring the prospectus reporting period

Neuracle's invasive brain-computer interface product received medical-device registration in March, but had not generated revenue during the reporting period covered by its prospectus. Its September 29 reply explains the technology alongside losses, R&D and customer accounts. Semiconductor applicants face questions about adoption and profitability, Shenzhen and Beijing listings reach the market, and regional measures address construction advances, board composition and advisory content.

Contents

An approval with commercialization still ahead

A medical-device approval is a major step for a brain-computer interface developer. It is not, however, a sale. Neuracle's September 29 IPO response and updated prospectus make that distinction unusually clear: the company says its invasive brain-computer interface product received registration in March 2026, while the prospectus reports no revenue from invasive BCI products during the period it covers.

The company's existing revenue and the prospects for its new technology therefore need to be read separately. The first can be measured through sales and cash flow. The second depends on the work between regulatory permission and repeat commercial use.

Elsewhere, semiconductor replies examine product adoption, customer dependence and profitability forecasts. Shenzhen welcomed two new listings. Financial-product online-marketing rules took effect, and the private-fund consultation reached its October 4 deadline. Regulatory measures addressed a construction advance, an improperly constituted board and investment-advisory communications.

Neuracle: what the fifth listing standard does and does not establish

Neuracle's filing uses the STAR Market's fifth listing standard. The route accommodates qualifying technology companies that have not reached profitability. It includes an expected market-value threshold of CNY4 billion and requirements concerning the business and core products; it is not a general exemption from having to explain the business or its funding needs.

Medical-device registration is also separate from securities registration. The former permits the product's approved medical use subject to the applicable conditions. The latter belongs to the IPO process. Neither one establishes the volume of future demand.

An invasive brain-computer interface involves an implanted component. Non-invasive systems collect signals without that implantation. Neuracle's reply treats the two categories separately, covering their technology, development and commercialization. That separation helps prevent readers from attributing the company's existing sales to a newly approved invasive product.

The September reply responds to an exchange letter issued in June. The new public event is the company's response, not a new September inquiry. Its thirteen groups of questions extend from core technology and invasive and non-invasive products to sales, revenue, margins, R&D, prototypes, receivables and contract assets. Neuracle response, contents and Questions 2–3, 5, 8–10.

The existing business has a measurable funding requirement

CNY million, except R&D ratio 2023 2024 2025 H1 2026
Revenue 75.2 66.0 108.5 46.3
Net profit / (loss) (48.8) (49.5) (230.5) (65.5)
Operating cash flow (50.7) (30.2) 9.5 (36.6)
R&D expenditure / revenue 84.94% 87.85% 60.02% 103.58%

Source: updated prospectus, PDF pp.30–31. Values rounded; parentheses indicate losses or cash outflows. H1 2026 covers six months and should not be compared with a full year as if the periods were equal.

Revenue recovered in 2025 after declining in 2024. Operating cash flow also turned positive, at CNY9.5 million. That positive year did not carry into the first half of 2026, when operations used CNY36.6 million of cash.

The prospectus identifies substantial R&D spending and share-based compensation in explaining losses. A non-cash compensation charge helps explain why a reported loss can be much larger than an operating cash outflow. It does not mean the company has reached operating profitability. The cost of development, the timing of customer payments and the resources needed to keep the business running remain separate questions.

The R&D ratio illustrates that funding requirement. In H1 2026, research spending exceeded revenue. That can be consistent with a company developing a new medical technology, but it makes the timing of commercialization consequential: a longer path to commercial scale can extend the period during which the business needs outside funding.

The proposed fundraising plan totals CNY2.5 billion: CNY1.776 billion for research, CNY174 million for production and CNY550 million for working capital. The updated prospectus notes that adjustments to the plan remain subject to shareholder approval. These are proposed uses of proceeds, not money already received or a schedule of assured sales.

What remains between registration and a repeat sale

The prospectus says commercialization of the invasive product is at an early stage and reports no invasive-product revenue over its reporting period. Readers therefore need milestones that can be tested in later filings: commercial deployments, customer acceptance, the form of payment, repeat orders and the support costs associated with use.

For a medical technology, a technically successful procedure and a sustainable commercial relationship are related but different achievements. Hospitals may need training, equipment, service arrangements and a payment mechanism. These are factors to examine, not claims that a particular obstacle has prevented Neuracle from selling its product.

The reply's prototype and customer-account questions are relevant here. Equipment supplied for development, evaluation or demonstration should not be confused with a completed revenue-generating sale. Receivables and contract assets, in turn, need to be connected to the remaining contractual steps and expected payment dates.

This is why the registration milestone deserves attention without doing all the work of a revenue forecast. Later disclosures of accepted deployments and cash receipts will make the commercial story much easier to assess.

Semiconductor replies make adoption assumptions more explicit

Yunbao Intelligent published a response to Shenzhen's review-center follow-up letter on September 30. The letter, issued September 24, asks for further support for the projected profitability date, including product development, orders and the assumptions for unit sales. It specifically raises the time between trial deployment, small orders and volume supply.

That sequence is important for a DPU developer serving computing infrastructure. Customer validation can establish that a product works in a particular environment. It is not equivalent to a commitment to recurring large purchases. The response also addresses competing suppliers' latest products and the corresponding risk disclosure. Yunbao follow-up response, PDF pp.3–5.

Xihe Technology's September 28 second-round reply presents a different customer-concentration issue. According to the exchange question, its June 30 order book was CNY3.279 billion, with 97.94% attributable to the ten largest customers. The filing also distinguishes products already generating revenue from next-generation optical-interconnect products still in customer validation.

An order book is useful evidence, but it still needs delivery schedules, cancellation terms and a connection to recognized revenue and collections. Concentration can magnify the effect of one customer's changed investment timetable. Forecasts about the wider optical-chip market should also distinguish sales available to independent suppliers from chips that integrated manufacturers produce for their own use. Xihe second-round response, Question 1.

Oriental Crystal's September 29 first-round response covers electron-beam semiconductor measurement and inspection equipment and manufacturing EDA software. The questions include continuing losses, revenue recognition, equipment upgrades and replacements, related businesses, margins and inventory. The response states that its figures reflect accounting-error corrections.

For an equipment supplier, product competitiveness has to connect with acceptance and replacement terms. An upgraded machine can be part of a valuable long-term customer relationship, while still requiring a clear account of what happens to the old equipment, the consideration paid and the point at which revenue is earned. Oriental Crystal response, Questions 1, 3–6 and 10.

Listings bring materials, nickel and auto parts to the market

Hongfucheng began trading on ChiNext on September 29 under code 301716. The company makes thermal-management and electromagnetic-shielding and absorbing materials. Shenzhen's listing announcement reports 2025 revenue of CNY707 million and net profit of approximately CNY269.1 million.

Its offering comprised approximately 18.73 million new shares at CNY76.86 each, raising about CNY1.44 billion before expenses. Those figures describe an actual offering, rather than an applicant's proposed fundraising target. Shenzhen listing announcement.

Lygend Resources, code 001246, scheduled its Shenzhen main-board listing for September 30. The company's principal business combines nickel-product trading and production, giving its revenue a different exposure to the commodity cycle from a materials manufacturer such as Hongfucheng. Its listing notice records an offering of 172.89 million new shares. Lygend listing notice, business risk disclosure and listing particulars.

On the Beijing exchange, Huzhou Anda Auto Parts' listing notice sets September 29 as the first trading day under code 920202. The company develops and manufactures precision aluminum-alloy die-cast automotive parts. Its initial offering of 28 million shares at CNY7.55 raised CNY211.4 million before expenses, with approximately CNY186.2 million remaining after issuance costs. Those figures exclude full exercise of the over-allotment option.

Anda's filing identifies the first listing standard, using the option requiring an expected market value of at least CNY200 million, latest-year profit of at least CNY25 million and a weighted return on equity of at least 8%. It reports 2025 profit of CNY62.6 million on the lower-of-reported-and-adjusted attributable-profit basis and a 14.40% return on equity on that basis. This earnings-based entry route differs from Neuracle's fifth-standard application.

The automobile exposure has a more specific qualification. Anda's risk section reports that combustion-engine vehicle business accounted for 78.76% of main-business revenue in the latest of its three annual comparison periods. Its expansion into lightweight components therefore sits alongside a substantial existing business whose customer mix and end-market transition matter. Anda's issuer listing notice, PDF pp.46–51 and 75–77.

The week thus includes companies arriving at the trading stage as well as applicants still explaining their forecasts. Those stages should not be conflated: a detailed response is part of review, whereas a listing notice follows the offering process.

Online-marketing rules now apply to financial-product promotion

The Financial Product Online Marketing Measures took effect on September 30. Eight authorities, including the CSRC and the People's Bank of China, issued the rules in April to govern how financial institutions and their internet partners promote products and services.

The institution must take responsibility for its marketing content, with centralized review and records. Platforms and staff using public accounts, livestreams or short videos must use approved material. Key information must match the product contract and be displayed clearly. The rules prohibit misleading claims, implied guarantees and selective performance presentations that mislead investors.

For firms working with outside platforms, the practical change is a defined control process, not simply a disclaimer attached to an advertisement. Written arrangements, partner assessment and continuing monitoring sit alongside content approval. Outsourcing marketing does not remove the institution's responsibility. For readers, the provider's identity and the terms of the actual product should be apparent, whatever channel delivers the promotion. Measures, Articles 7–10, 16 and 20–23.

A consultation closes; a tourism REIT receives approval

October 4 was the deadline for comments on the CSRC's private-fund fundraising proposal, published September 4. The proposal concerns investor qualification, funding-source checks, account arrangements and fundraising records. The close of consultation does not itself put the draft into force. The next policy development to follow is the final text and any implementation arrangements. CSRC consultation.

On September 30, the CSRC approved registration of the CICC Kaiyuan Tourism Commercial REIT. The decision specifies a contractual closed-end fund with a thirty-four-year term and 600 million units, managed by CICC Fund with CITIC Bank as custodian. The 600 million figure is a number of units, not an amount of money raised.

The approval sets a period for beginning fundraising and a maximum offering period. It is a product-specific registration decision, not a new rule for the REIT market or proof that the offering has already been completed. CSRC registration decision.

Regional measures connect paperwork to actual control

The Anhui bureau's warning concerning Yabaoxuan, published September 30 and dated September 28, identifies a CNY12 million construction advance paid in July 2024 contrary to the contract and failures in oversight and reporting. It also identifies related-party sales for which the required approval and disclosure procedures were not followed. The company and four responsible officers received warnings.

For directors, finance staff and advisers, the case points to the moment cash leaves the company. A signed construction contract is not enough if an advance departs from its payment conditions. Related-party checks likewise need to operate before approval and disclosure are due, not after the accounts have been prepared. Anhui decision.

The Ningbo bureau ordered Xianfeng New Materials to correct a board-composition problem: the July 17 election of two non-independent directors and one independent director did not comply with its articles, and the company had not promptly completed a further election. The order requires a report within thirty working days of receipt. The issue concerns compliance with the company's actual governance arrangements, not a new board-composition rule. Ningbo decision.

The Heilongjiang bureau's September 30 publication concerning Rongwei Securities Investment Consulting addresses unapproved adviser accounts, inadequate review of articles and livestreams, and problematic public investment-advisory content. It orders correction and a three-month suspension of new clients, together with a rectification report within thirty days. Resumption is subject to the bureau's review of remediation. Heilongjiang decision.

These are different failures, but each concerns a control that should have been active before the public consequence: before a payment, before a board takes office, or before advisory content reaches investors. The measures are regulatory orders and warnings, not fines where the decisions do not impose one.

Sources

Disclaimer

This article examines public records relating to the reporting period. It is for research and educational purposes and is not investment, legal or accounting advice, or a recommendation concerning any security. Official findings are attributed to the relevant authority; analytical observations are not findings of misconduct. Public documents may subsequently be corrected or supplemented.

Figure